A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.

@article{Center2010API,
  title={A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.},
  author={Brian Center and W Jeffrey Petty and Diandra N Ayala and William H. Hinson and James F Lovato and James Capellari and Timothy E Oaks and Antonius A. Miller and Arthur William Blackstock},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2010},
  volume={5 1},
  pages={69-74}
}
BACKGROUND Concurrent radiation and chemotherapy is the standard of care for good performance status patients with stage III non-small cell lung cancer. Locoregional control remains a significant factor relating to poor outcome. Preclinical and early clinical data suggest that docetaxel and gefitinib have radiosensitizing activity. This study sought to define the maximum tolerated dose of weekly docetaxel that could be given with daily gefitinib and concurrent thoracic radiation therapy… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…